Gene · 51135
Papers3,419
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 3,419
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| New approaches to the management of cutaneous lupus. | Curr Opin Rheumatol | 2026 | 42319220 | PubTator, text mining | PubMed |
| Ethnopharmacological investigation of Elaeocarpus sylvestris leaf extract in mitigating atopic dermatitis-like lesions via inflammatory signaling modulation. | J Ethnopharmacol | 2026 | 42314808 | PubTator, text mining | PubMed |
| m6A-Mediated Glycolysis by IL-37 Drives T Cell Metabolic Reprogramming to Regulate Colitis. | Adv Sci (Weinh) | 2026 | 42263254 | PubTator, text mining | PubMed |
| A heterobifunctional IRAK4-targeting degrader impairs myddosome signaling in acute kidney injury and ameliorates kidney fibrosis. | Commun Biol | 2026 | 42178364 | PubTator, text mining | PubMed |
| IRAK2 deficiency causes immune dysregulation through defective Myddosome assembly and enhanced interferon responses. | Nat Commun | 2026 | 42168171 | PubTator, text mining | PubMed |
| Compound heterozygous variants in IRAK4 cause IRAK4 deficiency characterized by recurrent bacterial infections, brain calcification, and severe epilepsy. | Gene | 2026 | 42103176 | PubTator, text mining | PubMed |
| Discovery of GSI526: a potent IRAK4-targeting PROTAC degrader with efficient degradation and suppression of inflammatory signaling. | Bioorg Med Chem Lett | 2026 | 42097519 | PubTator, text mining | PubMed |
| Local ancestry inference identifies robust evidence of selection in Neolithic Europe. | bioRxiv | 2026 | 42094542 | PubTator, text mining | PubMed |
| An integrative machine learning and structure-driven drug repositioning strategy for human IRAK4-targeted cancer therapy. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | 42059929 | PubTator, text mining | PubMed |
| Design, synthesis and pharmacological evaluation of 3H-spiro[benzofuran-2,4'-piperidine] IRAK4 inhibitors for the treatment of diffuse large B-cell lymphoma. | RSC Med Chem | 2026 | 42037740 | PubTator, text mining | PubMed |
| Interleukin enhancer binding factor 3 exacerbates cardiac inflammation and injury following myocardial infarction by inhibiting Lys48-linked ubiquitination on HNRNPA2B1 in macrophages. | Cell Mol Immunol | 2026 | 42020716 | PubTator, text mining | PubMed |
| Corrigendum to "Acanthoic acid protectsagainst ethanol-induced liver injury: Possible role of AMPK activation and IRAK4 inhibition" [Toxicol. Lett. 281 (2017) 127-138]. | Toxicol Lett | 2026 | 42002432 | PubTator, text mining | PubMed |
| Exome sequencing enables molecular diagnosis in 10% of early-onset or familial systemic lupus erythematosus cases. | EBioMedicine | 2026 | 41930824 | PubTator, text mining | PubMed |
| Neuroimaging Findings and Treatment Update for Neuroinflammation, Autoinflammation, Splenomegaly, and Anemia, a Novel Autoinflammatory Disorder Caused by Bi-Allelic Variants in IRAK4. | AJNR Am J Neuroradiol | 2026 | 41927338 | PubTator, text mining | PubMed |
| Chaperonin in health and disease. | Mol Biomed | 2026 | 41920440 | PubTator, text mining | PubMed |
| Exploring Synergistic Anti-Psoriatic Potential of Bioactive Compounds Tyrosol and Farnesol through In-Silico and In Vitro Approaches. | Curr Protein Pept Sci | 2026 | 41863454 | PubTator, text mining | PubMed |
| Primary Sjögren's syndrome-associated immune thrombocytopenia: from pathogenesis to treatment. | Front Immunol | 2026 | 41859115 | PubTator, text mining | PubMed |
| Emerging Paradigms in Immune-Focused Drug Discovery. | ACS Med Chem Lett | 2026 | 41847655 | PubTator, text mining | PubMed |
| Prospects and advances of PROTAC in the treatment of hematologic malignancies. | Exp Hematol Oncol | 2026 | 41845415 | PubTator, text mining | PubMed |
Association between plasma concentrations of galectin 3, growth differentiation factor 15, soluble suppression of tumourigenicity 2, and cystatin C and clinical parameters and survival in patients with end-stage renal disease undergoing haemodialysis. | Amino Acids | 2026 | 41824076 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51135/papers?page=2